NASDAQ:HTBX - Heat Biologics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.45 +0.03 (+2.11 %) (As of 02/17/2019 04:00 PM ET)Previous Close$1.45Today's Range$1.40 - $1.5052-Week Range$0.95 - $4.30Volume888,109 shsAverage Volume508,106 shsMarket Capitalization$33.72 millionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina. Receive HTBX News and Ratings via Email Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HTBX Previous Symbol CUSIPN/A Webwww.heatbio.com Phone919-240-7133Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.51 million Price / Sales22.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book1.05Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-11,840,000.00 Net Margins-331.02% Return on Equity-94.53% Return on Assets-51.39%Miscellaneous Employees19 Outstanding Shares23,257,000Market Cap$33.72 million OptionableNot Optionable Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions What is Heat Biologics' stock symbol? Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX." When did Heat Biologics' stock split? How did Heat Biologics' stock split work? Heat Biologics shares reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split. How were Heat Biologics' earnings last quarter? Heat Biologics Inc (NASDAQ:HTBX) announced its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.05. The biopharmaceutical company had revenue of $1.84 million for the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative net margin of 331.02% and a negative return on equity of 94.53%. View Heat Biologics' Earnings History. When is Heat Biologics' next earnings date? Heat Biologics is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Heat Biologics. What price target have analysts set for HTBX? 3 Wall Street analysts have issued 1-year price targets for Heat Biologics' shares. Their predictions range from $6.00 to $11.00. On average, they anticipate Heat Biologics' stock price to reach $8.50 in the next year. This suggests a possible upside of 486.2% from the stock's current price. View Analyst Price Targets for Heat Biologics. What is the consensus analysts' recommendation for Heat Biologics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics. Has Heat Biologics been receiving favorable news coverage? Media headlines about HTBX stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Heat Biologics earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. Who are some of Heat Biologics' key competitors? Some companies that are related to Heat Biologics include Aerpio Pharmaceuticals (ARPO), Cue Biopharma (CUE), Correvio Pharma (CORV), Unum Therapeutics (UMRX), Northwest Biotherapeutics (NWBO), Trevena (TRVN), Sol Gel Technologies (SLGL), Fortress Biotech (FBIO), Humanigen (HGEN), Galmed Pharmaceuticals (GLMD), Mustang Bio (MBIO), Checkpoint Therapeutics (CKPT), DURECT (DRRX), Corvus Pharmaceuticals (CRVS) and Chembio Diagnostics (CEMI). Who are Heat Biologics' key executives? Heat Biologics' management team includes the folowing people: Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)Ms. Ann A. Rosar, VP of Fin., Controller & Sec. (Age 67)Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)Dr. Justin Stebbing, Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor Who are Heat Biologics' major shareholders? Heat Biologics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include CVI Holdings LLC (6.70%) and Virtu Financial LLC (0.24%). View Institutional Ownership Trends for Heat Biologics. Which institutional investors are buying Heat Biologics stock? HTBX stock was bought by a variety of institutional investors in the last quarter, including CVI Holdings LLC and Virtu Financial LLC. View Insider Buying and Selling for Heat Biologics. How do I buy shares of Heat Biologics? Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Heat Biologics' stock price today? One share of HTBX stock can currently be purchased for approximately $1.45. How big of a company is Heat Biologics? Heat Biologics has a market capitalization of $33.72 million and generates $1.51 million in revenue each year. Heat Biologics employs 19 workers across the globe. What is Heat Biologics' official website? The official website for Heat Biologics is http://www.heatbio.com. How can I contact Heat Biologics? Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected] MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 250 (Vote Outperform)Underperform Votes: 179 (Vote Underperform)Total Votes: 429MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: Why is the LIBOR significant?